CCL2 and nonpapillary renal cell carcinoma: Kanno and co-workers found that JunB increased in VHL-defective ccRCC samples, and JunB knockdown inhibited invasiveness of VHL-null ccRCC cells by controlling the expression of MMP2, MMP9 and chemokine (C-C motif) ligand-2 (CCL2).